Publication details

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients

Authors

BOHOŠOVÁ Júlia JURÁČEK Jaroslav POPRACH Alexandr KOPECKY J. FIALA O. SVOBODA Marek FABIAN Pavel RADOVÁ Lenka BRABEC Petr BUCHLER T. SLABÝ Ondřej

Year of publication 2019
Type Article in Periodical
Magazine / Source CANCER GENOMICS & PROTEOMICS
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://cgp.iiarjournals.org/content/16/5/353.full
Doi http://dx.doi.org/10.21873/cgp.20140
Keywords Renal cell carcinoma; sunitinib; microRNA; prediction
Description Background/Aim: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. Patients and Methods: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. Results: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). Conclusion: A predictive miRNA associated with progression free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.
Related projects: